Latest Forum Topics /
Clearbridge
Last:0.001
-0.001
|
 Post Reply
|
|
Medical Stock - Strong Shareholders
|
|||||
|
newbie888
Veteran |
15-May-2020 21:27
|
||||
|
x 0
x 0 Alert Admin |
Maybe you are right? 🙂
|
||||
| Useful To Me Not Useful To Me | |||||
|
Justice888
Supreme |
15-May-2020 21:15
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge sales high but profits little . Low profit margin. Eg I earn $5k can save $2k.. my fren earn $10k . No savings . In reality I am better ?
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
newbie888
Veteran |
15-May-2020 21:07
|
||||
|
x 0
x 0 Alert Admin |
Obviously during this period medtec will be much better since ppe is much needed during a pandemic no doubt.. Must look at the long run to gauge which is the Co. More worthy to hold for the long term?
|
||||
| Useful To Me Not Useful To Me | |||||
|
deathztm
Senior |
15-May-2020 21:05
|
||||
|
x 0
x 0 Alert Admin |
$2000 dollars profit. u all still huating this stock? the amount of money of your share in it sure more than $2000. hope for the best on monday | ||||
| Useful To Me Not Useful To Me | |||||
|
churnw
Elite |
15-May-2020 20:56
|
||||
|
x 0
x 0 Alert Admin |
Both are different type
CB provide service. Medtec provide product . Except both are in medical field ... |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
shaz87
Member |
15-May-2020 20:39
|
||||
|
x 0
x 0 Alert Admin |
Revenue increase from Q1 2019 to 2020: Medtecs - 137.6% Clearbridge - 230.8% Surely this is good news for CBH, right?
|
||||
| Useful To Me Not Useful To Me | |||||
|
wolverine23
Supreme |
15-May-2020 20:06
Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!" |
||||
|
x 0
x 0 Alert Admin |
haha how to compare? Medtecs results are simply fantastic
|
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
15-May-2020 19:56
|
||||
|
x 0
x 0 Alert Admin |
Revenue increased by 230.8% or S$5.11 million from S$2.21 million in Q1 FY2019 to S$7.32 million in Q1 FY2020, driven by growth across (i) medical clinics/centres and (ii) healthcare systems (provision of clinical laboratory services and renal care services) segments.
Excluding the non-recurring item such as fair value losses/gains on other investments, associate and other derivative financial instruments, fair value adjustments on contingent consideration, non-recurring expenses, share-based payment as well as foreign exchange loss/gain, the Group has recorded positive adjusted EBITDA of S$0.04 million in Q1 FY2020 as compared to adjusted EBITDA loss of S$1.15 million in Q1 FY2019.
Q1 FY2020 Business Update
Extension on call option
&bull As disclosed in the Company&rsquo s offer document dated 11 December 2017, the Group has an option to purchase the interests held by SPRING Seeds Capital Pte. Ltd. (&ldquo SEEDS&rdquo ) in Biolidics Limited (the &ldquo Biolidics Call Option&rdquo ). The expiry of the Biolidics Call Option has been extended from 28 February 2020 to 28 November 2020.
Proposed disposal of shares in Biomedics Laboratory Pte Ltd (&ldquo Biomedics&rdquo )
&bull On 27 March 2020, the Company&rsquo s wholly-owned subsidiary, SAM Laboratory Pte Ltd (&ldquo SAM&rdquo ) entered into a conditional sale and purchase agreement with Biolidics Limited to dispose of the entire issued and paid-up capital of Biomedics Laboratory Pte. Ltd. (&ldquo Biomedics&rdquo ) held by SAM for a consideration of up to S$3.7 million (the &ldquo Proposed Disposal&rdquo ).
&bull As set out in the Company&rsquo s announcement dated 27 March 2020, the Proposed Disposal will enable the Group to, among others, better focus on distribution of clinical diagnostics tests by channelling resources to expanding its distribution capabilities across Asia. In addition, the Group will continue to have access to the services currently offered by Biomedics and other best-in-class technologies and workflows that Biomedics may offer while optimising its EBITDA-focused strategy to accelerate the adoption of precision medicine in the region.
Impact of COVID-19
&bull The COVID-19 outbreak had evolved into a global pandemic. Most businesses, including the usually resilient healthcare sector, have been affected adversely to varying degrees. While our medical centres/clinics and laboratories remained opened during 1Q FY2020, majority of our operations has experienced a smaller patient load as the movement of people was curtailed. In some countries, foreign patients are prohibited from coming to seek medical care and non-critical healthcare services are deferred in effort to contain the spread of the COVID-19 pandemic.
&bull In view of the above, we will continue to monitor the situation and its financial impact for the financial year ending 31 December 2020 and will provide updates should there be material developments affecting to the Group.
Pls see here for more details: https://links.sgx.com/FileOpen/Clearbridge_Q1%20FY2020%20Quarterly%20results.ashx?App=Announcement& FileID=611116
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Timer78
Veteran |
15-May-2020 19:54
|
||||
|
x 0
x 0 Alert Admin |
Do some maths pls. Loss to profit whats the percentage gain?
Red ink prob a thing of the past now as PE is forward looking. Dyodd.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Goldfinger
Supreme |
15-May-2020 19:38
|
||||
|
x 0
x 0 Alert Admin |
Disappointing results - Medtecs did much better. | ||||
| Useful To Me Not Useful To Me | |||||
|
Laurenpanna
Veteran |
15-May-2020 19:32
|
||||
|
x 0
x 0 Alert Admin |
This is only Q1 , we are mid way into Q2 already. and at least it is not negative. Let' s see how it goes .
|
||||
| Useful To Me Not Useful To Me | |||||
|
jie1313
Member |
15-May-2020 19:23
|
||||
|
x 0
x 0 Alert Admin |
Loss to net profit. But only $2k profit. Wonder will Mr Market like this. Hmm.. | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Fluffyclouds
Master |
15-May-2020 19:00
|
||||
|
x 0
x 0 Alert Admin |
I see positive PROFIT and HIGH revenue (high sales).
High expenses are justifiable for their case. 🎉 🎉 🎉 Once all the expansion needed then it is set in for growth. I read quite extensively their past p&l years. All are good! But again do your own research! All the best guysssssss. Good weekend. Now can drink kopi with extra sugar today. |
||||
| Useful To Me Not Useful To Me | |||||
|
churnw
Elite |
15-May-2020 18:57
|
||||
|
x 0
x 0 Alert Admin |
Have not talk about bio at all ...
which they have not put in their profit ... |
||||
| Useful To Me Not Useful To Me | |||||
|
Laurenpanna
Veteran |
15-May-2020 18:56
|
||||
|
x 0
x 0 Alert Admin |
Hurray ! everyone! Let' s rejoice for the weekend and welcome Monday ! |
||||
| Useful To Me Not Useful To Me | |||||
|
newbie888
Veteran |
15-May-2020 18:56
|
||||
|
x 0
x 0 Alert Admin |
It's a nice result brothers. Positive ebita and starting to see profit. But how woukd covid affect cbh. We shall hope for the best | ||||
| Useful To Me Not Useful To Me | |||||
|
genting^2
Master |
15-May-2020 18:55
|
||||
|
x 0
x 0 Alert Admin |
Revenue &bull Revenue increased by 230.8% or S$5.11 million from S$2.21 million in Q1 FY2019 to S$7.32 million in Q1 FY2020, driven by growth across (i) medical clinics/centres and (ii) healthcare systems (provision of clinical laboratory services and renal care services) segments. &bull Healthcare systems recorded a revenue of S$4.86 million in Q1 FY2020 which increased by S$3.55 million, from S$1.31 million in Q1 FY2019. The increase was mainly contributed by PT Indo Genesis Medika (&ldquo IGM Labs&rdquo ) of S$3.44 million. IGM Labs was acquired in May 2019. Revenue (cont&rsquo d) &bull Medical clinics/centres recorded a revenue of S$2.46 million in Q1 FY2020, an increase of S$1.56 million, from S$0.90 million in Q1 FY2019. This was mainly due to contributions of S$1.62 million from nine dental clinics which were acquired by the Group in late August 2019 and the medical clinics/centres operations in Hong Kong and the Philippines from sales of medical supplies. However, the increase was partially offset by a decrease in revenue from the medical clinics/centres operations in Singapore which were affected by the COVID-19 pandemic since early March 2020. &bull In comparison with the Group&rsquo s revenue in Q4 FY2019 of S$8.28 million, the Group&rsquo s revenue in Q1 FY2020 decreased by 11.6% or S$0.96 million to S$7.32 million in Q1 FY2020, mainly due to decrease in revenue from IGM Labs and medical clinics/centres operations in Singapore and the Philippines. This was mainly due to deferment and restrictions of non-critical healthcare needs to contain the spread of COVID-19 pandemic. Expenses &bull Expenses comprise mainly purchases, employee benefits expense, depreciation & amortization expenses, other operating expenses, fair value losses/gains on associate and derivative financial instruments. The increase in expenses was in line with the growth in revenue, acquisitions completed in Q2 FY2019 and Q3 FY2019 and loan financing taken in FY2019. |
||||
| Useful To Me Not Useful To Me | |||||
|
xKaiseRx
Veteran |
15-May-2020 18:53
|
||||
|
x 0
x 0 Alert Admin |
lets see how the market move on monday... | ||||
| Useful To Me Not Useful To Me | |||||
|
ken777
Veteran |
15-May-2020 18:52
|
||||
|
x 0
x 0 Alert Admin |
$2000 in dollar term profit
|
||||
| Useful To Me Not Useful To Me | |||||
|
rlong8288
Master |
15-May-2020 18:48
|
||||
|
x 0
x 0 Alert Admin |
Wow.what is the actual profit in dollar terms
|
||||
| Useful To Me Not Useful To Me | |||||